Investor Presentation First Nine Months of 2023

4 Investor presentation First nine months of 2023 Novo NordiskⓇ Strategic Aspirations 2025 | Highlights first nine months of 2023 Purpose and sustainability (ESG) Progress towards zero environmental impact Carbon emissions decreased by 28% vs first 9M 20191 Adding value to society Medical treatment to ~40 million people with diabetes Reached more than 46,000 children in Changing Diabetes in Children programme Partnership with Aspen to produce human insulin for Africa Being recognised as a sustainable employer Share of women in senior leadership positions has increased to 41% from 38% at end of September 2022 therapeutic focus Innovation and . • Light blue indicates developments in Q3 2023 Further raise innovation bar for Diabetes treatment Regulatory submission of once-weekly insulin icodec Initiation of phase 3 trial with CagriSema T2D FLOW stopped for efficacy based on interim analysis Develop superior treatment solutions for obesity Regulatory submission of SELECT CVOT Strengthen and progress Rare Disease pipeline Concizumab approved for HAWI/HBwI in Japan Establish presence in other serious chronic diseases Acquisition of ocedurenone within CVD Commercial execution Diabetes value market share increased by 1.8%-points to 33.3%² Obesity care sales of DKK 30.4 billion (+174% at CER) Rare disease sales of DKK 12.6 billion (-18% at CER) Financials Sales growth of 33% (CER) and operating profit growth of 37% (CER) Operational leverage reflecting sales growth Free cash flow of DKK 75.6 billion and DKK 52.0 billion returned to shareholders 1Scope 1,2 and partial scope 3 limited to CO2 emissions from business flights and product distribution; 2MAT (Moving annual total) value market share CER: Constant exchange rates; 9M: Nine months; HAWI/HBWI: Haemophilia A/B with inhibitors Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth

View entire presentation